Real-Time Precision Psychiatry for Schizophrenia: A Microfluidic Genotyping and Super-Learner Platform for Treatment Response Prediction.

A Super Learner ensemble model combines pharmacogenomic profile, clinical data and medication to predict PANSS reduction, backed by a microfluidic chip that genotypes 13 SNPs.

Antipsychotic treatment response in schizophrenia varies widely between patients, and current pharmacogenomic models integrate multimodal factors and real-time decision-making needs poorly. In a retrospective development cohort (2019-2021, N = 735), the authors built a Super Learner ensemble model (five machine learning algorithms) predicting PANSS reduction from pharmacogenomic profiles, clinical characteristics and medication data, with features selected by random forest recursive feature elimination (RF-RFE), and validated it in an external cohort (2021-2022, N = 90). The root mean square error (RMSE) was 7.08 in cross-validation (R² = 0.89) and 9.02 in external validation (R² = 0.76). For 13 prioritised single-nucleotide polymorphisms (SNPs), a microfluidic chip based on kompetitive allele-specific PCR (KASP) was developed and compared with Sanger sequencing in 24 clinical samples, with 100% concordance; a clinical decision support tool combining genotyping and predictive analytics was deployed, with sample-to-report feasibility demonstrated within 3 hours.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

The cross-validated R² of 0.89 falls to 0.76 in only 90 external patients, and nothing in the abstract says what the 13 SNPs add over clinical and medication variables alone, or against which reference model performance is compared: the share of genotype in the prediction is not established. The predicted endpoint is PANSS reduction, not the effect of a treatment choice guided by the tool; no data show that using it improves patient course, and the abstract names neither the genes nor the antipsychotics involved. The 100% chip concordance on 24 samples and the 3-hour turnaround establish technical feasibility, a prerequisite rather than proof of clinical usefulness.

Analysis by Dr Thibaut Benquey